Michael Makris Shares French Regulatory Update: Marstacimab (Hympavzi) Not Recommended for Severe Haemophilia A or B
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, shared a post on Linkedin:
“Interesting development from France. The French authorities assessed marstacimab (Hympavzi) and concluded that it has no place in the therapeutic strategy for severe haemophilia A or B without inhibitors.
They questioned the robustness of the comparative assessment against other approved therapies and pointed to uncertainties in terms of safety.
The document is in French but Google translate does a pretty good job if you do not speak French. I attach the Google translate version of the conclusion. ”
Check out here for more.
Find more posts on Hemostasis Today.
-
Aug 31, 2025, 14:26Diego Segura-Rodríguez Shares ESC/EACTS Consensus on Post-CABG Antithrombotic Therapy
-
Aug 31, 2025, 09:45Slow Uptake of Hemophilia Gene Therapies: Challenges in Access and Adoption
-
Aug 30, 2025, 14:43Abdulla A. Damluji Questions Evidence for Beta-Blockers After MI Without Heart Failure
-
Aug 30, 2025, 14:42BDCC Future Leaders ’26: Empowering Teens Like Sarada Venigalla to Share Their Stories
-
Aug 30, 2025, 14:39Michael Makris Shares French Regulatory Update: Marstacimab (Hympavzi) Not Recommended for Severe Haemophilia A or B
-
Aug 31, 2025, 12:39Lupus Anticoagulant and Antiphospholipid Syndrome: Insights from Local Practice
-
Aug 31, 2025, 10:55NEJM Study: Aspirin with Oral Anticoagulation Raises Risks in Chronic Coronary Syndrome
-
Aug 31, 2025, 07:29Marcin Kurzyna: ESC Guidelines on Pregnancy and Cardiovascular Disease Highlight Updates in VTE Treatment
-
Aug 30, 2025, 14:44Sarah C. Hull: Evidence Supports Plant-Forward Diets, Not Raw Milk or Beef Tallow Trends
-
Aug 30, 2025, 14:43Extended Low-Dose Apixaban Reduces Risk of Recurrent VTE: HI-PRO Trial Results
-
Aug 29, 2025, 09:03Vasculearn Network: New 2025 High Blood Pressure Guidelines Are Here
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Aug 18, 2025, 23:50Safe and Efficient Thrombectomy with Artix System: Clinical Insights from Neil Desai and Colleagues
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Aug 30, 2025, 14:45Gordon’s Journey: 60 Years of Life After DVT Managed with Warfarin
-
Aug 29, 2025, 19:10Mount Sinai’s Dr. Krittika Pant to Present Watchman Device Thrombosis Analysis at ESC Congress 2025
-
Aug 29, 2025, 09:02Flora Peyvandi: Join the Hemostasis Community at BIC 2025 in Italy
-
Aug 26, 2025, 09:42David McIntosh Highlights Global Blood Shortages and Fresh vs Stored RBCs
-
Aug 23, 2025, 07:48Protecting Heart and Brain Health: Stroke Prevention in Women with Bleeding Disorders: NBDF